Do these shares get back to the 2020 highs that were reached back in January?
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
A simple covered call strategy seems appropriate here.
The short-term charts of VRTX suggest that this stock can see further sideways to lower price action in the weeks ahead.
BMY sees reason for optimism over the final half of the year.
There is no thought of selling here and now, even with politicized pressure on the industry.
Biotechnology is always high risk but the right plays move unlike anything else.
Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.
Let's review the charts and indicators.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.